CYP1B1 is highly upregulated within pulmonary arterial lesions of PAH patients and pharmacological inhibition of CYP1B1 can attenuate the development of experimental pulmonary hypertension. This evidence concerns the gene CYP1B1 and pulmonary arterial hypertension.